Hace 8 años | Por Pezzonovante a nature.com
Publicado hace 8 años por Pezzonovante a nature.com

El primer medicamento producido por un musgo tiene el visto bueno para entrar en ensayos clínicos. Reguladores alemanes dieron permiso en septiembre a Greenovation Biotech para iniciar un ensayo clínico de fase 1 para evaluar "moss-aGal", una forma recombinante de galactosidasa alfa humana, como tratamiento de reemplazo enzimático para la enfermedad de Fabry. El musgo, a diferencia de otras plantas, no produce proteínas hiperglicosiladas, inmunogénicas en seres humanos.

Comentarios

D

Cultívate tu medicina. Mola.

Pezzonovante

Esta es la noticia completa, creo que hay un paywall:

"The world's first moss-produced drug candidate has the go-ahead to enter clinical trials. German regulators in September told Greenovation Biotech of Freiburg that it could begin a phase 1 clinical trial evaluating moss-aGal, a recombinant form of human alpha galactosidase, as an enzyme replacement treatment for Fabry disease. Like all plants, moss engage in post-translational modification of proteins, but unlike other plants, it does not make hyperglycosylated proteins that are immunogenic in humans. Greenovation's moss, Physcomitrella patens, produces predominantly N-mannose terminated proteins. This improves uptake by cell-surface mannose receptors throughout the body, potentially qualifying this product as a “biobetter.” Moss has several other attractive features: its genome is only 511 Mbps, and it is haploid whereas other plant systems are diploid or polyploid. In addition, moss predominantly uses a homologous recombination system for repair, which makes gene replacement efforts more efficient. Several versions of alpha galactosidase are on the market or under development: Fabrazyme (agalsidase beta) from Sanofi/Genzyme of Paris, which has been in short supply since 2009, Replagal (agalsidase alfa) from San Diego's Shire, and another plant-produced (carrot and tobacco) recombinant version of this enzyme, called PRX-102, developed by Protalix BioTherapeutics of Carmiel, Israel." CC #1

mikibastar

#1 Cultiva tu medicina con plantas transgénicas.... mola mucho.

D

Aquí no saldrá ningún gilipollas diciendo que los transgénicos son malos.